Personalized therapy on the horizon for squamous cell carcinoma of the lung

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Lung squamous cell carcinoma (SQCC) is a major cause of cancer death, representing the second-largest subtype of non-small cell lung cancer (NSCLC).
• Existing targeted therapies for NSCLC primarily benefit lung adenocarcinoma, leaving a significant unmet need for SQCC treatment.
• Advances in cancer genome sequencing have revealed potential therapeutic targets in various cancers.

Purpose of the Study:

• To review the current genomic landscape of lung SQCC.
• To summarize ongoing clinical trials for targeted agents in lung SQCC.
• To identify and suggest novel actionable mutations for future personalized SQCC therapies.

Main Methods:

• Comprehensive genomic characterization of lung SQCC using massively parallel sequencing.
• Review of current literature on lung SQCC genomic alterations.
• Analysis of ongoing clinical trials for targeted agents in lung SQCC.

Main Results:

• Identification of potential driver mutations and signaling pathways in lung SQCC, including FGFR1 amplifications, PI3KCA mutations, PTEN mutations/deletions, PDGFRA amplifications/mutations, and DDR2 mutations.
• Highlighting the disparity in targeted therapy availability between lung adenocarcinoma and SQCC.
• Establishing a foundation for personalized medicine in lung SQCC.

Conclusions:

• Genomic discoveries offer new hope for developing targeted therapies for lung SQCC.
• Further investigation of identified biomarkers and novel actionable mutations is crucial for advancing personalized treatment strategies.
• The findings pave the way for future clinical trials aimed at improving outcomes for lung SQCC patients.